Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Liver Cirrhosis

Free Subscription Articles published in Gut Retrieve available abstracts of 73 articles: HTML format

Single Articles

April 2024
1. ARMANDI A, Sanavia T, Younes R, Caviglia GP, et al
   Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease.
   Gut. 2024;73:825-834.
   PubMed     Abstract available
   
   
   March 2024
2. TREBICKA J, Hernaez R, Shawcross DL, Gerbes AL, et al
   Recent advances in the prevention and treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) and the role of biomarkers.
   Gut. 2024 Mar 25:gutjnl-2023-330584. doi: 10.1136/gutjnl-2023-330584.
   PubMed     Abstract available
   
   
   February 2024
3. EL-SERAG H, Kanwal F, Ning J, Powell H, et al
   Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis.
   Gut. 2024 Feb 16:gutjnl-2024-332034. doi: 10.1136/gutjnl-2024-332034.
   PubMed     Abstract available
   
   
   January 2024
4. 
   Correction: P23 Opportunistic cirrhosis case finding in alcohol dependent inpatients through alcohol specialist nurse assessment and transient elastography: early detection in a high-risk group.
   Gut. 2024;73:e3.
   PubMed    
   
   
   
5. KONG M, Zhou J, Kang A, Kuai Y, et al
   Histone methyltransferase Suv39h1 regulates hepatic stellate cell activation and is targetable in liver fibrosis.
   Gut. 2024 Jan 4:gutjnl-2023-329671. doi: 10.1136/gutjnl-2023-329671.
   PubMed     Abstract available
   
   
   December 2023
6. CHOUIK Y, Levrero M
   Monocyte phenotypic liquid biopsy for NASH and liver fibrosis diagnosis: a new kid on the block.
   Gut. 2023;73:10-11.
   PubMed    
   
   
   November 2023
7. ZHANG X, Yip TC, Wong GL, Leow WX, et al
   Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial.
   Gut. 2023;72:2364-2371.
   PubMed     Abstract available
   
   
   
8. 
   Correction: Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET).
   Gut. 2023;72:e4.
   PubMed    
   
   
   October 2023
9. JUANOLA A, Ma AT, de Wit K, Gananandan K, et al
   Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis.
   Gut. 2023 Oct 26:gutjnl-2023-329923. doi: 10.1136/gutjnl-2023-329923.
   PubMed     Abstract available
   
   
   
10. CHOI WM, Kim GA, Choi J, Choi GH, et al
    Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B.
    Gut. 2023 Oct 9:gutjnl-2023-330225. doi: 10.1136/gutjnl-2023-330225.
    PubMed     Abstract available
    
    
    
11. CIOCAN D, Turpin W
    New insights into an old paradigm: why IgA accumulates in alcoholic liver disease and what could be its role.
    Gut. 2023;72:1812-1814.
    PubMed    
    
    
    July 2023
12. HE X, Gao N, Lv F, Wu F, et al
    Temporal trend of mortality in patients with cirrhosis with primary biliary cholangitis and primary sclerosing cholangitis during the COVID-19 pandemic.
    Gut. 2023 Jul 24:gutjnl-2023-330271. doi: 10.1136/gutjnl-2023-330271.
    PubMed    
    
    
    
13. MANTOVANI A, Csermely A, Tilg H, Byrne CD, et al
    Comparative effects of non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease on risk of incident cardiovascular events: a meta-analysis of about 13 million individuals.
    Gut. 2023;72:1433-1436.
    PubMed    
    
    
    June 2023
14. WITTKOP L, Boettler T
    More than shots in the dark: driving vaccine efficacy in cirrhosis.
    Gut. 2023 Jun 7:gutjnl-2023-329867. doi: 10.1136/gutjnl-2023-329867.
    PubMed    
    
    
    March 2023
15. GIRALDEZ-GALLEGO A, Rodriguez-Seguel EDP, Valencia-Martin R, Morillo-Garcia A, et al
    Three double-dose reinforced hepatitis B revaccination scheme for patients with cirrhosis unresponsive to the standard regimen: an open-label randomised clinical trial.
    Gut. 2023 Mar 24:gutjnl-2022-328222. doi: 10.1136/gutjnl-2022-328222.
    PubMed     Abstract available
    
    
    
16. LOOMBA R, Huang DQ, Sanyal AJ, Anstee QM, et al
    Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.
    Gut. 2023;72:581-589.
    PubMed     Abstract available
    
    
    February 2023
17. WEISS E, de la Pena-Ramirez C, Aguilar F, Lozano JJ, et al
    Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET).
    Gut. 2023 Feb 14:gutjnl-2022-328708. doi: 10.1136/gutjnl-2022-328708.
    PubMed     Abstract available
    
    
    January 2023
18. RAVAIOLI F, Dajti E, Mantovani A, Newsome PN, et al
    Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis.
    Gut. 2023 Jan 4:gutjnl-2022-328689. doi: 10.1136/gutjnl-2022-328689.
    PubMed     Abstract available
    
    
    
19. EFFENBERGER M, Widjaja AA, Grabherr F, Schaefer B, et al
    Interleukin-11 drives human and mouse alcohol-related liver disease.
    Gut. 2023;72:168-179.
    PubMed     Abstract available
    
    
    
20. HERNAEZ R, Peck-Radosavljevic M
    MAFLD, HCC and the dilemma of (changing) terminology in liver diseases.
    Gut. 2023;72:9-11.
    PubMed    
    
    
    December 2022
21. RAO J, Wang H, Ni M, Wang Z, et al
    FSTL1 promotes liver fibrosis by reprogramming macrophage function through modulating the intracellular function of PKM2.
    Gut. 2022;71:2539-2550.
    PubMed     Abstract available
    
    
    November 2022
22. BAJAJ JS, Pena-Rodriguez M, La Reau A, Phillips W, et al
    Longitudinal transkingdom gut microbial approach towards decompensation in outpatients with cirrhosis.
    Gut. 2022 Nov 7. pii: gutjnl-2022-328403. doi: 10.1136/gutjnl-2022-328403.
    PubMed     Abstract available
    
    
    
23. THEVENOT T, Desmarets M, Weil D, Di Martino V, et al
    Diameter of the shunt: the missing link in the appraisal of pTIPS in patients with cirrhosis with previous hepatic encephalopathy.
    Gut. 2022 Nov 3. pii: gutjnl-2022-328761. doi: 10.1136/gutjnl-2022-328761.
    PubMed    
    
    
    
24. DUFOUR JF, Marjot T, Becchetti C, Tilg H, et al
    COVID-19 and liver disease.
    Gut. 2022;71:2350-2362.
    PubMed     Abstract available
    
    
    September 2022
25. KULKARNI AV, Metage CS, Gora BA, Tirumalle S, et al
    SARS-CoV-2 Omicron variant infection was associated with higher morbidity in patients with cirrhosis.
    Gut. 2022 Sep 16. pii: gutjnl-2022-328451. doi: 10.1136/gutjnl-2022-328451.
    PubMed    
    
    
    
26. RUDLER M, Hernandez-Gea V, Procopet BD, Giraldez A, et al
    Hepatic encephalopathy is not a contraindication to pre-emptive TIPS in high-risk patients with cirrhosis with variceal bleeding.
    Gut. 2022 Sep 9. pii: gutjnl-2022-326975. doi: 10.1136/gutjnl-2022-326975.
    PubMed     Abstract available
    
    
    
27. ZHAO Y, Yeo YH, Samaan J, Lv F, et al
    Most excess years of potential life loss among individuals with cirrhosis during the pandemic were not related to COVID-19.
    Gut. 2022 Sep 5. pii: gutjnl-2022-328188. doi: 10.1136/gutjnl-2022-328188.
    PubMed    
    
    
    
28. JOHN BV, Bastaich DR, Ferreira RD, Doshi A, et al
    COVID-19 vaccine effectiveness and community prevalence of Alpha, Delta and Omicron variants in patients with cirrhosis.
    Gut. 2022 Sep 5:gutjnl-2022-327799. doi: 10.1136/gutjnl-2022-327799.
    PubMed    
    
    
    
29. SIMON TG, Roelstraete B, Hagstrom H, Sundstrom J, et al
    Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort.
    Gut. 2022;71:1867-1875.
    PubMed     Abstract available
    
    
    July 2022
30. ANGELINI G, Panunzi S, Castagneto-Gissey L, Pellicano F, et al
    Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis.
    Gut. 2022 Jul 12. pii: gutjnl-2022-327498. doi: 10.1136/gutjnl-2022-327498.
    PubMed     Abstract available
    
    
    
31. BUCH S, Innes H, Lutz PL, Nischalke HD, et al
    Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study.
    Gut. 2022 Jul 4. pii: gutjnl-2022-327196. doi: 10.1136/gutjnl-2022-327196.
    PubMed     Abstract available
    
    
    
32. PAVLIDES M, Mozes FE, Harrison SA
    Reply to: Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?
    Gut. 2022;71:1453-1454.
    PubMed    
    
    
    
33. SALHAB A, Amer J, Lu Y, Safadi R, et al
    Sodium(+)/taurocholate cotransporting polypeptide as target therapy for liver fibrosis.
    Gut. 2022;71:1373-1385.
    PubMed     Abstract available
    
    
    June 2022
34. AWONIYI M, Wang J, Ngo B, Meadows V, et al
    Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC.
    Gut. 2022 Jun 15. pii: gutjnl-2021-326500. doi: 10.1136/gutjnl-2021-326500.
    PubMed     Abstract available
    
    
    
35. MAJUMDAR A, Tsochatzis EA
    Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?
    Gut. 2022;71:1236-1237.
    PubMed    
    
    
    May 2022
36. GORGULU E, Gu W, Trebicka J, Mucke VT, et al
    Acute-on-chronic liver failure (ACLF) precipitated by severe alcoholic hepatitis: another collateral damage of the COVID-19 pandemic?
    Gut. 2022;71:1036-1038.
    PubMed    
    
    
    
37. MOZES FE, Lee JA, Selvaraj EA, Jayaswal ANA, et al
    Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.
    Gut. 2022;71:1006-1019.
    PubMed     Abstract available
    
    
    March 2022
38. JUANOLA A, Mezzano G, Hamilton JP, Gines P, et al
    Reply to: "Acute-on-chronic liver failure in East-Asia: an underestimated issue with limited data".
    Gut. 2022;71:657-658.
    PubMed    
    
    
    
39. HADERER M, Neubert P, Rinner E, Scholtis A, et al
    Novel pathomechanism for spontaneous bacterial peritonitis: disruption of cell junctions by cellular and bacterial proteases.
    Gut. 2022;71:580-592.
    PubMed     Abstract available
    
    
    February 2022
40. CAO Z, Xie Q
    Acute-on-chronic liver failure in East Asia: an underestimated issue with limited data.
    Gut. 2022;71:445-446.
    PubMed    
    
    
    January 2022
41. SCHULZ M, Trebicka J
    Acute-on-chronic liver failure: a global disease.
    Gut. 2022;71:5-6.
    PubMed    
    
    
    December 2021
42. HUNG CT, Su TH, Chen YT, Wu YF, et al
    Targeting ER protein TXNDC5 in hepatic stellate cell mitigates liver fibrosis by repressing non-canonical TGFbeta signalling.
    Gut. 2021 Dec 21. pii: gutjnl-2021-325065. doi: 10.1136/gutjnl-2021-325065.
    PubMed     Abstract available
    
    
    
43. MACKEN L, Palaniyappan N, Verma S, Aithal G, et al
    Large volume paracentesis: to do or where to do?
    Gut. 2021;70:2401-2402.
    PubMed    
    
    
    
44. AFONSO MB, Rodrigues PM, Mateus-Pinheiro M, Simao AL, et al
    RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.
    Gut. 2021;70:2359-2372.
    PubMed     Abstract available
    
    
    October 2021
45. TRIVEDI PJ, Hirschfield GM
    Recent advances in clinical practice: epidemiology of autoimmune liver diseases.
    Gut. 2021;70:1989-2003.
    PubMed     Abstract available
    
    
    
46. JUNG J, Loomba RR, Imajo K, Madamba E, et al
    MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.
    Gut. 2021;70:1946-1953.
    PubMed     Abstract available
    
    
    August 2021
47. KHAMRI W, Gudd C, Liu T, Nathwani R, et al
    Suppressor CD4(+) T cells expressing HLA-G are expanded in the peripheral blood from patients with acute decompensation of cirrhosis.
    Gut. 2021 Aug 3. pii: gutjnl-2021-324071. doi: 10.1136/gutjnl-2021-324071.
    PubMed     Abstract available
    
    
    July 2021
48. SIMON TG, Roelstraete B, Khalili H, Hagstrom H, et al
    Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.
    Gut. 2021;70:1375-1382.
    PubMed     Abstract available
    
    
    June 2021
49. PARK H, Yoon EL, Cho S, Jun DW, et al
    Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease.
    Gut. 2021 Jun 14. pii: gutjnl-2021-325102. doi: 10.1136/gutjnl-2021-325102.
    PubMed    
    
    
    May 2021
50. ARMANDI A, Schattenberg JM
    NAFLD between genes and environment: what drives fibrogenesis?
    Gut. 2021;70:815-816.
    PubMed    
    
    
    April 2021
51. XIE Z, Gao Y, Ho C, Li L, et al
    Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment.
    Gut. 2021 Apr 7. pii: gutjnl-2020-323014. doi: 10.1136/gutjnl-2020-323014.
    PubMed     Abstract available
    
    
    March 2021
52. JACKSON K, Davidson R, Aujayeb A
    Hepatic hydrothorax in the management of cirrhosis.
    Gut. 2021 Mar 31. pii: gutjnl-2021-324698. doi: 10.1136/gutjnl-2021-324698.
    PubMed    
    
    
    February 2021
53. FROMME M, Schneider CV, Pereira V, Hamesch K, et al
    Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency.
    Gut. 2021 Feb 25. pii: gutjnl-2020-323729. doi: 10.1136/gutjnl-2020-323729.
    PubMed     Abstract available
    
    
    
54. BARCENA-VARELA M, Paish H, Alvarez L, Uriarte I, et al
    Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis.
    Gut. 2021;70:388-400.
    PubMed     Abstract available
    
    
    January 2021
55. PETROFF D, Batz O, Jedrysiak K, Kramer J, et al
    Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples.
    Gut. 2021;70:219-221.
    PubMed    
    
    
    October 2020
56. BAYO J, Fiore EJ, Dominguez LM, Cantero MJ, et al
    Bioinformatic analysis of RHO family of GTPases identifies RAC1 pharmacological inhibition as a new therapeutic strategy for hepatocellular carcinoma.
    Gut. 2020 Oct 26. pii: gutjnl-2020-321454. doi: 10.1136/gutjnl-2020-321454.
    PubMed     Abstract available
    
    
    
57. PRAKTIKNJO M, Schierwagen R, Monteiro S, Ortiz C, et al
    Hepatic inflammasome activation as origin of Interleukin-1alpha and Interleukin-1beta in liver cirrhosis.
    Gut. 2020 Oct 21. pii: gutjnl-2020-322621. doi: 10.1136/gutjnl-2020-322621.
    PubMed    
    
    
    
58. AITHAL GP, Palaniyappan N, China L, Harmala S, et al
    Guidelines on the management of ascites in cirrhosis.
    Gut. 2020 Oct 16. pii: gutjnl-2020-321790. doi: 10.1136/gutjnl-2020-321790.
    PubMed     Abstract available
    
    
    
59. TRANAH TH, Edwards LA, Schnabl B, Shawcross DL, et al
    Targeting the gut-liver-immune axis to treat cirrhosis.
    Gut. 2020 Oct 15. pii: gutjnl-2020-320786. doi: 10.1136/gutjnl-2020-320786.
    PubMed     Abstract available
    
    
    
60. IAVARONE M, D'Ambrosio R, Lampertico P
    Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19.
    Gut. 2020 Oct 7. pii: gutjnl-2020-322929. doi: 10.1136/gutjnl-2020-322929.
    PubMed    
    
    
    September 2020
61. BAJAJ JS, Sikaroodi M, Shamsaddini A, Henseler Z, et al
    Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.
    Gut. 2020 Sep 30. pii: gutjnl-2020-322470. doi: 10.1136/gutjnl-2020-322470.
    PubMed     Abstract available
    
    
    
62. ESPARZA-BAQUER A, Labiano I, Sharif O, Agirre-Lizaso A, et al
    TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.
    Gut. 2020 Sep 9. pii: gutjnl-2019-319227. doi: 10.1136/gutjnl-2019-319227.
    PubMed     Abstract available
    
    
    July 2020
63. GEIER A, Boursier J
    Non-invasive diagnosis of patients with 'at-risk' NAFLD : only fibrosis counts?
    Gut. 2020;69:1164-1165.
    PubMed    
    
    
    June 2020
64. THANGAPANDI VR, Knittelfelder O, Brosch M, Patsenker E, et al
    Loss of hepatic Mboat7 leads to liver fibrosis.
    Gut. 2020 Jun 26. pii: gutjnl-2020-320853. doi: 10.1136/gutjnl-2020-320853.
    PubMed     Abstract available
    
    
    
65. BREITKOPF-HEINLEIN K, Syn WK
    Harnessing liver progenitors in the treatment of liver fibrosis: a step in the right direction?
    Gut. 2020;69:975-976.
    PubMed    
    
    
    
66. DAI Z, Song G, Balakrishnan A, Yang T, et al
    Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells.
    Gut. 2020;69:1104-1115.
    PubMed     Abstract available
    
    
    
67. WANG Y, Wong GL, He FP, Sun J, et al
    Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy.
    Gut. 2020;69:1116-1126.
    PubMed     Abstract available
    
    
    March 2020
68. SCHATTENBERG JM
    Prevention of endpoints in primary biliary cholangitis with ursodeoxycholic acid: quantifying the benefit.
    Gut. 2020 Mar 23. pii: gutjnl-2019-320355. doi: 10.1136/gutjnl-2019-320355.
    PubMed    
    
    
    February 2020
69. LOOMBA R, Adams LA
    Advances in non-invasive assessment of hepatic fibrosis.
    Gut. 2020 Feb 17. pii: gutjnl-2018-317593. doi: 10.1136/gutjnl-2018-317593.
    PubMed     Abstract available
    
    
    January 2020
70. DROPMANN A, Dooley S, Dewidar B, Hammad S, et al
    TGF-beta2 silencing to target biliary-derived liver diseases.
    Gut. 2020 Jan 28. pii: gutjnl-2019-319091. doi: 10.1136/gutjnl-2019-319091.
    PubMed     Abstract available
    
    
    December 2019
71. HARMS MH, de Veer RC, Lammers WJ, Corpechot C, et al
    Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
    Gut. 2019 Dec 16. pii: gutjnl-2019-319057. doi: 10.1136/gutjnl-2019-319057.
    PubMed     Abstract available
    
    
    October 2019
72. CHEN Y, Lin XY
    Are the 5-hydroxymethylcytosine-based wd-scores really superior over alpha-fetoprotein for the early diagnosis of hepatocellular carcinoma?
    Gut. 2019 Oct 25. pii: gutjnl-2019-319853. doi: 10.1136/gutjnl-2019-319853.
    PubMed    
    
    
    September 2019
73. MARTI-RODRIGO A, Alegre F, Moragrega AB, Garcia-Garcia F, et al
    Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells.
    Gut. 2019 Sep 17. pii: gutjnl-2019-318372. doi: 10.1136/gutjnl-2019-318372.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge.